MedPath

Bepotastine Besilate

These highlights do not include all the information needed to use BEPOTASTINE BESILATE OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for BEPOTASTINE BESILATE OPHTHALMIC SOLUTION. BEPOTASTINE BESILATE ophthalmic solution, for topical application in the eyeInitial U.S. Approval: 2009

Approved
Approval ID

75178670-aa57-45f9-94d5-efcf8305e683

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 20, 2018

Manufacturers
FDA

Mylan Pharmaceuticals Inc.

DUNS: 059295980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Bepotastine Besilate

PRODUCT DETAILS

NDC Product Code0378-7055
Application NumberANDA206220
Marketing CategoryC73584
Route of AdministrationOPHTHALMIC
Effective DateMarch 20, 2018
Generic NameBepotastine Besilate

INGREDIENTS (6)

BEPOTASTINE BESILATEActive
Quantity: 15 mg in 1 mL
Code: 6W18MO1QR3
Classification: ACTIB
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATEInactive
Code: 5QWK665956
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Bepotastine Besilate - FDA Drug Approval Details